pharmaphorum

MARCH 19, 2021

The oceans of health data out there can be overwhelming for pharma companies to manage – but if extracted correctly, the prospect to develop drugs from scratch in as little as a year is very real, says Lifebit CEO, Dr Maria Chatzou Dunford. . on Big data: astronomical or genomical? ,

Bioinformatics 59

Bioinformatics Drugs Genome Genomics 59

pharmaphorum

OCTOBER 20, 2021

The trial – which will be supported by pharma company Eisai and Ionian University in the US – will see if the test can identify people who have mild cognitive impairment (MCI) due to Alzheimer’s disease. ” The post Eisai-backed trial will assess Altoida’s digital test for early Alzheimer’s appeared first on.

Trials 78

Trials Genome Genomics Bioinformatics 78

pharmaphorum

APRIL 7, 2022

During the initial stage of the collaboration, Ares developed a an AI-powered anti-infectives platform using microbiological lab techniques and bioinformatics that can be used to identify effective antimicrobial compounds or combinations against specific pathogens, which Sandoz can use to inform its “portfolio and commercial decisions.”

Bioinformatics 52

Bioinformatics Genetics Genome Genomics 52

Drug Discovery World

JULY 19, 2023

Evan Floden , CEO of Seqera Labs examines how data sharing platforms are impacting cancer and genomics research. Increasingly, major collaborative life sciences projects, like the Human Genome Project or Human Cell Atlas, are driving advancements and organisations – both public and private – are taking note.

Genome 52

Genome Genomics Bioinformatics Genetics 52

XTalks

DECEMBER 13, 2023

Now, let’s delve into the list of the top ten fastest growing biotech companies in 2023, ranked by their compound annual growth rate (CAGR). These companies were identified through The Americas’ Fastest-Growing Companies 2023 list by the Financial Times.

Genetics 111

Genetics Vaccination Vaccine DNA 111

pharmaphorum

MARCH 28, 2022

Built under a government tender, AION Labs comprises four large international pharma companies – AstraZeneca , Merck, Pfizer , and Teva – and another core partner, the Israel Biotech Fund. At times, companies invest millions of dollars in developing and studying a therapy that may find to be ineffective. The partnership.

Pharma Companies 98

Pharma Companies Antibody Protein Development 98

Drug Discovery World

NOVEMBER 15, 2022

Gene-to-antibody production begins with scientists entering antibody sequences as starting material, after which bioinformatics tools filter out potentially non-viable sequences. Then, using DNA synthesis capabilities, oligo pools encoding for specific domains of the antibody are generated as libraries and cloned into a vector.

DNA 98

DNA Drugs Antibody Engineer 98